Celularity vs Proqr Therapeutics
Celularity is the larger business, with $26.6m of revenue in fiscal 2025 against $18.0m for Proqr Therapeutics (1.5 times as much). Proqr Therapeutics grew faster (-12.1% against -51.0%). Proqr Therapeutics kept more of each dollar of sales as profit: a net margin of -265.2% against -345.4%.
| Latest fiscal year | CelularityCELU, 2025 | Proqr TherapeuticsPRQR, 2025 |
|---|---|---|
| Revenue | $26.6m | $18.0m |
| Revenue growth | -51.0% | -12.1% |
| Net income | −$91.7m | −$47.7m |
| Operating margin | -230.9% | -273.1% |
| Net margin | -345.4% | -265.2% |
| Return on equity | — | -63.8% |
| Free cash flow | −$13.3m | −$60.8m |
| Cash | $6.2m | $108m |
| Total debt | $33.8m | $5.7m |
| Debt to equity | — | 9.9% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 115 | — |
| Market value | $24.0m | $144m |
| Price vs our value range | — | — |
| Moat score | 18 (Weak) | — |
| Insider trades, 12 months | 0 buys, 0 sales | 5 buys, 0 sales |